Use of Indocyanine green(ICG) dye for axilla treatment in breast cancer patients

Use of Indocyanine green (ICG) dye for Sentinel lymph node biopsy in Breast cancer patients - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074039

Enrollment

Registered

2024-09-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: INDOCYANINE GREEN DYE: USING INDOCYANINE GREEN DYE FOR FOR SENTINEL LYMPHN NODE BIOPSY for 1 year Control Intervention1: nill: nill

Eligibility

Inclusion criteria

Inclusion criteria: upfront operable breast cancer patients

Exclusion criteria

Exclusion criteria: 1. Known allergy to iodine/ ICG 2. Post neo-adjuvant chemotherapy patients 3. Patients refusing for the study 4. Pregnancy associated breast cancer

Design outcomes

Primary

Measure	Time frame
Identification of sentinel nodes( identification rate) and their pathological assessment ( positive rate) by frozen section.Timepoint: 1 year	—

Secondary

Measure	Time frame
safety feasibilityTimepoint: 1 year	—

Countries

India

Contacts

Public ContactJnaneshwari Jayaram

Father Muller Medical College,

jnaneshwari.j@fathermuller.in09742954025

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026